0
Abstract: Poster Presentations |

EFFECT OF BOSENTAN ON THE PROGRESSIVE WORSENING OF PULMONARY VASCULAR REMODELLING AND PULMONARY HYPERTENSION ASSOCIATED WITH MODERATE/SEVERE COPD: RESULTS OF 18 MONTHS OF TREATMENT FREE TO VIEW

Pietro B. Bracciale, MD*; Salvatore Bellanova, MD; Antonio Castagnaro, MD; Anna Grazia D’Agostino, MD; Liliana Mangiacotti, MD; Cristina Scoditti, MD; Giuseppe Valerio, MD
Author and Funding Information

Department of Respiratory Disease, ASL BR/1, San Pietro Vernotico, Italy


Chest


Chest. 2009;136(4_MeetingAbstracts):61S-c-62S. doi:10.1378/chest.136.4_MeetingAbstracts.61S-c
Text Size: A A A
Published online

Abstract

PURPOSE:  Pulmonary Hypertension(PH) associated to Chronic Obstructive Pulmonary Disease (COPD) III-IV GOLD stage is well-known related to hypoxemia. Pulmonary vascular remodelling (PVR), with organic changes of vessels, is frequently present.It is well demonstrated that Endothelin plays a important role on the pathogenesis of PVR and PH.

METHODS:  Our aim was to assess the effect of endothelin receptor antagonist, Bosentan,125 mg b.i.d., administered to 16 patients affected by PH and COPD for 18 months, on the progressive worsening of PVR and PH. Pulmonary function test, echo-cardiac-doppler, cardio-pulmonary TC with retrospective gating, rigth heart catheterization,effort performance(6MWT), blood gas analysis and quality of life were performed at the beginning and at the end of the study. Median pulmonary artery pressure (PAP) like or more of 25mmHg at rest was considered significant Control group was 16 patients with overlapping cinical features.

RESULTS:  30 percent of patients showed significant improvement of PH, PVR, effort performance.The patients in which vascular remodelling was well established, did not showed improvement but, at the same time, did not showed worsening of parameters cited above.

CONCLUSION:  In all patients, the regular treatment with Bosentan 125 mg b.i.d., can antagonize the progressive worsening of PVR and PH. Futhermore, we obtained improvement of 6MWT, cariovascular performance, dyspnoea, prognosis.

CLINICAL IMPLICATIONS:  It should be useful early treatment of patients affected by PH and COPD III-IV GOLD stage, before pathologic vessels changes taken place.

DISCLOSURE:  Pietro Bracciale, No Financial Disclosure Information; No Product/Research Disclosure Information

Tuesday, November 3, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543